Highly Enantioselective Pd-Catalyzed Asymmetric Hydrogenation of N-Diphenylphosphinyl Ketimines

You-Qing Wang; Yong-Gui Zhou

doi:10.1055/s-2006-939712

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000083.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Synlett 2006(8): 1189-1192
DOI: 10.1055/s-2006-939712

LETTER

Highly Enantioselective Pd-Catalyzed Asymmetric Hydrogenation of N-Diphenylphosphinyl Ketimines

You-Qing Wang, Yong-Gui Zhou*
Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, P. R. of China
Fax: +86(411)84379220; e-Mail: ygzhou@dicp.ac.cn;

Further Information

Publication History

Received 16 November 2005
Publication Date:
05 May 2006 (online)

Abstract
Full Text
References

Buy Article Permissions and Reprints All articles of this category

Abstract

A variety of substituted N-diphenylphosphinyl imines were hydrogenated using Pd(CF₃CO₂)₂/(S)-SEGPHOS as a catalyst with high enantioselectivities (86.7%-98.6% ee).

Key words

palladium - asymmetric synthesis - hydrogenation - N-diphenylphosphinyl imines

References and Notes

1a Comprehensive Asymmetric Catalysis Jacobsen EN. Pfaltz A. Yamamoto H. Springer; New York: 1999.
1b Catalytic Asymmetric Synthesis Ojima I. Wiley-VCH; New York: 2000. 2nd ed:
2a Tsuji J. Palladium Reagents and Catalysis John Wiley & Sons; Chichester: 2004.

Crossref PubMed
2b Negishi E. Handbook of Organopalladium Chemistry for Organic Synthesis Wiley; Hoboken NJ: 2002.

Crossref PubMed
2c Heck RF. Pd Reagents in Organic Synthesis Academic; New York: 1985.

Crossref PubMed
2d Tietze LF. Ila H. Bell HP. Chem. Rev. 2004, 104: 3453

Crossref PubMed Search in Google Scholar
3a Noyori R. Angew. Chem. Int. Ed. 2002, 41: 2008

Crossref PubMed Search in Google Scholar
3b Knowles WS. Angew. Chem. Int. Ed. 2002, 41: 1998

Crossref PubMed Search in Google Scholar
3c Rossen K. Angew. Chem. Int. Ed. 2001, 40: 4611

Crossref PubMed Search in Google Scholar
3d Tang W. Zhang X. Chem. Rev. 2003, 103: 3029

Crossref PubMed Search in Google Scholar
For reviews on the asymmetric hydrogenation of imines, see:
4a Kobayashi S. Ishitani H. Chem. Rev. 1999, 99: 1069

Search in Google Scholar
4b Brunel JM. Recent Res. Dev. Org. Chem. 2003, 7: 155

Search in Google Scholar
4c Liu P. Jiang H.-F. Chin. J. Org. Chem. 2004, 24: 1317

Search in Google Scholar
Recent literature on heterogeneous Pd asymmetric hydrogenation:
5a Studer M. Blaser H.-U. Exner C. Adv. Synth. Catal. 2003, 345: 45

Crossref Search in Google Scholar
5b Tungler A. Fogassy G. J. Mol. Catal. A: Chem. 2001, 173: 231

Crossref Search in Google Scholar
5c Blaser H.-U. Indolese A. Schnyder A. Steiner H. Studer M. J. Mol. Catal. A: Chem. 2001, 173: 3

Crossref Search in Google Scholar
5d Li C. Catal. Rev. 2004, 46: 419

Crossref Search in Google Scholar
5e Glorius F. Spielkamp N. Holle S. Goddard R. Lehmann CW. Angew. Chem. Int. Ed. 2004, 43: 2850

Crossref Search in Google Scholar
5f Raynor SA. Thomas JM. Raja R. Johnson BFG. Bell RG. Mantle MD. Chem. Commun. 2000, 1925

Crossref
6a Abe H. Amii H. Uneyama K. Org. Lett. 2001, 3: 313

Crossref PubMed Search in Google Scholar
6b Suzuki A. Mae M. Amii H. Uneyama K. J. Org. Chem. 2004, 69: 5132

Crossref PubMed Search in Google Scholar
7 Nanayakkara P. Alper H. Chem. Commun. 2003, 2384

Crossref
8 Wang Y.-Q. Lu S.-M. Zhou Y.-G. Org. Lett. 2005, 7: 3235

Crossref PubMed Search in Google Scholar
9a Krzyzanowska B. Stec WJ. Synthesis 1982, 270

Crossref PubMed
9b Masumoto S. Usuda H. Suzuki M. Kainai M. Shibasaki M. J. Am. Chem. Soc. 2003, 125: 5634

Crossref PubMed Search in Google Scholar
Asymmetric hydrogenation of N-diphenylphosphinyl imines:
10a Rh complex: Spindler F. Blaser H.-U. Adv. Synth. Catal. 2001, 343: 68

Crossref PubMed Search in Google Scholar
10b Ir complex: Jiang X.-B. Minnaard AJ. Hessen B. Feringa BL. Duchateau ALL. Andrien JGO. Boogers JAF. de Vries JG. Org. Lett. 2003, 5: 1503

Crossref PubMed Search in Google Scholar
Asymmetric reduction of N-diphenylphosphinyl imines without hydrogen:
11a Yamada T. Nagata T. Sugi K. Yorozu K. Ikeno T. Ohtsuka Y. Miyazaki D. Mukaiyama T. Chem. Eur. J. 2003, 9: 4485

Crossref PubMed Search in Google Scholar
11b Hutchins RO. Magid AA. Stercho YP. Wambsgans A. J. Org. Chem. 1987, 52: 702

Crossref PubMed Search in Google Scholar
11c Lipshutz BH. Shimizu H. Angew. Chem. Int. Ed. 2004, 43: 2228

Crossref PubMed Search in Google Scholar
12 N-(Diphenylphosphinyl)amines 2 obtained by addition of diorganozinc to aldimines: Boezio AA. Pytkowicz J. Côté A. Charette AB. J. Am. Chem. Soc. 2003, 125: 14260

Crossref PubMed Search in Google Scholar

13

A series of additives were tested in the reaction of 1b: 3 Å MS (conversion: >95%, 96.4% ee), 5 Å MS (conversion: 72%, 96.4% ee), Na₂SO₄ (conversion: 64%, 96.4% ee).

14

Asymmetric Hydrogenation; Typical Procedure. (S)-SEGPHOS (2.9 mg, 0.0048 mmol) and Pd(CF₃CO₂)₂ (1.3 mg, 0.004 mmol) were placed in a dried Schlenk tube under a nitrogen atmosphere, and degassed anhydrous acetone was added. The mixture was stirred at r.t. for 1 h. The solvent was removed under vacuum to give the catalyst. This catalyst was placed in a nitrogen-filled glove box and dissolved in anhyd TFE (1 mL). To a mixture of 1a and 4 Å MS, the catalyst solution was added, and then the mixture was transferred to an autoclave. The hydrogenation was performed at r.t. under H₂ (1000 psi) for 8-12 h. The hydrogen was carefully released and the solvents were removed. Conversion was determined by ¹H NMR spectroscopy. The ee was determined by HPLC after purification on silica gel (hexanes-EtOAc-Et₃N, 1:2:0.02). The absolute configuration of 2a was determined by measurement of its optical rotation. N-Diphenylphosphinyl imines 1 were prepared according to the literature. [9] Racemates of N-(diphenylphosphinyl)amines were prepared by reduction of the corresponding imines using NaBH₄ in THF. For the preparation of complexes and other experimental details, see reference 8.

15

Compound 1c: white solid. ¹H NMR (400 MHz, CDCl₃): δ = 2.95 (d, J = 1.8 Hz, 3 H), 7.12-7.17 (m, 2 H), 7.43-7.45 (m, 6 H), 7.94-7.99 (m, 4 H), 8.09-8.12 (m, 2 H). ¹³C NMR (100 MHz, CDCl₃): δ = 23.1 (d, J = 12.3 Hz), 115.8 (d, J = 21.7 Hz), 128.6 (d, J = 12.3 Hz), 130.6 (d, J = 8.9 Hz), 131.7, 131.8, 134.8 (d, J = 130.2 Hz), 135.9 (d, J = 25.8 Hz), 165.7 (d, J = 252.7 Hz), 180.2 (d, J = 7.0 Hz). ³¹P NMR (162 MHz, CDCl₃): δ = 19.1. HRMS (ESI): m/z calcd for C₂₀H₁₈FNOP [M + H⁺]: 338.1105; found: 338.1082.
Compound 1f: white solid. ¹H NMR (400 MHz, CDCl₃): δ = 2.95 (d, J = 2.1 Hz, 3 H), 3.88 (s, 3 H), 7.10 (m, 1 H), 7.39-7.46 (m, 7 H), 7.64 (d, J = 2.4 Hz, 2 H), 7.95-8.00 (m, 4 H). ¹³C NMR (100 MHz, CDCl₃): δ = 23.3 (d, J = 12.4 Hz), 55.6, 113.6, 117.9, 120.7, 128.6 (d, J = 12.4 Hz), 129.7, 131.6, 131.7 (d, J = 9.0 Hz), 134.8 (d, J = 130.3 Hz), 141.0 (d, J = 23.9 Hz), 159.8, 181.5 (d, J = 7.5 Hz). ³¹P NMR (162 MHz, CDCl₃): δ = 19.3. HRMS (ESI): m/z calcd for C₂₁H₂₁NO₂P [M + H⁺]: 350.1304; found: 350.1297.
Compound 1g: white solid. ¹H NMR (400 MHz, CDCl₃): δ = 2.89 (d, J = 2.0 Hz, 3 H), 3.82 (d, J = 2.4 Hz, 3 H), 6.93 (d, J = 8.3 Hz, 1 H), 7.00 (s, 1 H), 7.40-7.45 (m, 7 H), 7.63 (dd, J = 1.7, 7.6 Hz, 1 H), 7.93-7.99 (m, 4 H). ¹³C NMR (100 MHz, CDCl₃): δ = 28.3 (d, J = 13.6 Hz), 55.5, 111.6, 120.6, 128.4 (d, J = 12.3 Hz), 129.9, 131.4, 131.8 (d, J = 8.9 Hz), 132.3, 134.9 (d, J = 129.2 Hz), 158.0, 186.0 (d, J = 7.6 Hz). ³¹P NMR (162 MHz, CDCl₃): δ = 18.5. HRMS (ESI): m/z calcd for C₂₁H₂₁NO₂P [M + H⁺]: 350.1304; found: 350.1288.
Compound 2a: white solid; 95.3% ee (R); [α]_D ²⁶ +38.3 (c 0.54, EtOH); R _f 0.14 (PE-EtOAc, 2:1); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 20:80, 1.0 mL/min, 254 nm): t _R 12.9 min (R), t _R 24.4 min (S). ¹H NMR (400 MHz, CDCl₃): δ = 1.58 (d, J = 6.7 Hz, 3 H), 3.17 (dd, J = 5.9, 9.1 Hz, 1 H), 4.36-4.43 (m, 1 H), 7.26-7.45 (m, 11 H), 7.80-7.85 (m, 2 H), 7.89-7.93 (m, 2 H).
Compound 2b: white solid; 96.6% ee (S); [α]_D ⁸ -66.5 (c 1.08, MeOH); R _f 0.22 (PE-EtOAc, 2:1); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80-20, 1.0 mL/min, 254 nm): t _R 11.4 min (R), t _R 15.8 min (S). ¹H NMR (400 MHz, CDCl₃): δ = 1.56 (d, J = 6.8 Hz, 3 H), 2.34 (s, 3 H), 3.14-3.17 (m, 1 H), 4.32-4.39 (m, 1 H), 7.15 (dd, J = 8.0, 20.4 Hz, 4 H), 7.37-7.48 (m, 6 H), 7.81-7.91 (m, 4 H).
Compound 2c: white solid; 94.0% ee (S); [α]_D ⁸ -41.9 (c 1.04, MeOH); R _f 0.18 (PE-EtOAc, 2:1); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80:20, 1.0 mL/min, 254 nm): t _R 10.0 min (R), t _R 27.0 min (S). ¹H NMR (400 MHz, CDCl₃): δ = 1.55 (d, J = 6.8 Hz, 3 H), 3.11 (dd, J = 5.9, 9.2 Hz, 1 H), 4.35-4.42 (m, 1 H), 6.98 (t, J = 8.7 Hz, 2 H), 7.23-7.25 (m, 2 H), 7.36-7.37 (m, 2 H), 7.44-7.46 (m, 4 H), 7.78-7.81 (m, 2 H), 7.88-7.92 (m, 2 H).
Compound 2d: white solid; 94.2% ee (S); [α]_D ⁸ -73.4 (c 1.14, MeOH); R _f 0.33 (PE-EtOAc, 1:1); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80:20, 1.0 mL/min, 254 nm): t _R 11.4 min (R), t _R 26.3 min (S). ¹H NMR (400 MHz, CDCl₃): δ = 1.55 (d, J = 6.8 Hz, 3 H), 3.17 (dd, J = 5.7, 9.5 Hz, 1 H), 4.33-4.40 (m, 1 H), 7.24 (dd, J = 8.5, 23.0 Hz, 4 H), 7.37-7.47 (m, 6 H), 7.79 (dd, J = 7.0, 12.0, 2 H), 7.90 (dd, J = 6.9, 11.9 Hz, 2 H).
Compound 2e: white solid; 96.0% ee (S); [α]_D ⁸ -66.4 (c 1.30, MeOH); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80:20, 1.0 mL/min, 254 nm): t _R 15.9 min (R), t _R 26.8 min (S). ¹H NMR (400 MHz, CDCl₃): δ = 1.55 (d, J = 6.7 Hz, 3 H), 3.12 (dd, J = 5.9, 9.4 Hz, 1 H), 3.80 (s, 3 H), 4.31-4.41 (m, 1 H), 6.85 (d, J = 8.7 Hz, 2 H), 7.21 (d, J = 8.7 Hz, 2 H), 7.37-7.48 (m, 6 H), 7.81-7.91 (m, 4 H).
Compound 2f: white solid; 96.0% ee (S); [α]_D ⁸ -52.1 (c 1.32, MeOH); R _f 0.38 (PE-EtOAc, 1:1); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80:20, 1.0 mL/min, 254 nm): t _R 14.5 min (R), t _R 29.4 min (S). ¹H NMR (400 MHz, CDCl₃): δ = 1.57 (d, J = 6.8 Hz, 3 H), 3.22 (dd, J = 5.9, 9.5 Hz, 1 H), 3.78 (s, 3 H), 4.31-4.39 (m, 1 H), 6.82-6.88 (m, 3 H), 7.21-7.23 (m, 1 H), 7.36-7.47 (m, 6 H), 7.80-7.93 (m, 4 H).
Compound 2g: white solid; 98.6% ee (S); [α]_D ⁸ -22.1 (c 1.13, MeOH); R _f 0.33 (PE-EtOAc, 1:1). HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80:20, 1.0 mL/min, 254 nm): t _R 11.9 min (R), t _R 21.3 min (S). ¹H NMR (400 MHz, CDCl₃): δ = 1.50 (d, J = 6.8 Hz, 3 H), 3.69 (s, 3 H), 3.87 (dd, J = 8.0, 10.5 Hz, 1 H), 4.36-4.43 (m, 1 H), 6.78-6.82 (m, 2 H), 6.97 (s, 1 H), 7.19 (t, J = 7.7 Hz, 1 H), 7.33-7.38 (m, 6 H), 7.72 (dd, J = 7.3, 11.9 Hz, 2 H), 7.79 (dd, J = 7.1, 11.8 Hz, 2 H). ¹³C NMR (100 MHz, CDCl₃): δ = 25.1, 49.6, 55.4, 111.2, 121.0, 128.3 (d, J = 7.0 Hz), 128.5, 131.7, 131.8, 128.1 (d, J = 108.6 Hz), 131.7, 131.8, 132.0 (d, J = 9.3 Hz), 132.8 (d, J = 9.4 Hz), 133.0, 133.1, 133.8 (d, J = 119.7 Hz), 157.0. ³¹P NMR (162 MHz, CDCl₃): δ = 22.9. HRMS (ESI): m/z calcd for C₂₁H₂₃NO₂P [M + H⁺], 352.1461; found, 352.1451.
Compound 2h: white solid; 86.7% ee (S); [α]_D ⁸ -38.5 (c 1.26, MeOH); R _f 0.31 (PE-EtOAc, 1:1); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80:20, 1.0 mL/min, 254 nm): t _R 9.6 min (R), t _R 17.7 min (S). ¹H NMR (400 MHz, CDCl₃): δ = 0.79 (t, J = 7.4 Hz, 3 H), 1.80-1.89 (m, 1 H), 1.97-2.04 (m, 1 H), 3.25 (dd, J = 6.4, 9.4 Hz, 1 H), 4.08-4.11 (m, 1 H), 7.14-7.16 (m, 2 H), 7.23-7.33 (m, 5 H), 7.42-7.44 (m, 4 H), 7.73-7.87 (m, 4 H).
Compound 2i: white solid; 92.8% ee (S); [α]_D ⁸ -77.8 (c 1.02, MeOH); R _f 0.39 (PE-EtOAc, 1:1); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80:20, 1.0 mL/min, 254 nm): t _R 21.6 min (R), t _R 27.7 min (S). ¹H NMR (400 MHz, CDCl₃): δ = 1.66 (d, J = 6.7 Hz, 3 H), 3.27-3.31 (m, 1 H), 4.51-4.61 (m, 1 H), 7.32-7.33 (m, 2 H), 7.43-7.48 (m, 7 H), 7.65 (s, 1 H), 7.80-7.83 (m, 5 H), 7.93 (m, 2 H).
Compound 2j: white solid, 87.0% ee (S), [α]_D ⁸ -42.1 (c 0.60, CH₂Cl₂); R _f 0.34 (PE-CH₂Cl₂,1:4); HPLC (Chiralpak AS-H column, hexane-i-PrOH, 80:20, 1.0 mL/min, 254 nm): t _R 12.1 min (R), t _R 17.0 min (S). ¹H NMR (400 MHz, CDCl₃): δ = 1.60 (d, J = 6.8 Hz, 3 H), 3.19 (dd, J = 6.6, 10.3 Hz, 1 H), 4.38-4.44 (m, 1 H), 6.13 (d, J = 3.2 Hz, 1 H), 6.28 (dd, J = 1.9, 3.2 Hz, 1 H), 7.35 (m, 1 H), 7.42-7.49 (m, 6 H), 7.87-7.95 (m, 4 H).